Epigenome editing in cancer: Advances and challenges for potential therapeutic options
Authors:
- 20 November 2023
- book chapter
- Published by Elsevier
- Vol. 383, 191-230
Abstract
No abstract availableKeywords
Funding Information
- Knight Cancer Institute, Oregon Health and Science University (2018-CRUK-OHSU-001)
- Misophonia Research Fund (GCNCR1042A)
- Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University
This publication has 298 references indexed in Scilit:
- An iPSC Line from Human Pancreatic Ductal Adenocarcinoma Undergoes Early to Invasive Stages of Pancreatic Cancer ProgressionCell Reports, 2013
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumorsThe International Journal of Biochemistry & Cell Biology, 2009
- Genomic patterns of DNA methylation: targets and function of an epigenetic markCurrent Opinion in Cell Biology, 2007
- The Epigenomics of CancerCell, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerThe Prostate, 2004